过去十年，中国保险业经历了从"粗放扩张"向"精耕细作"的深刻变革，科技成为重塑行业格局的关键变量。 互联网保险公司就是科技浪潮最直接的见证者。 产品层面，该公司构建了分层保障体系：其中，面向大众健康的"微医保·百万医疗险"已迭代16次，成为普惠型医疗险的典型代表；针对高端需求推出提供 全国找医、全球找药服务的高端医疗险；"好效保"系列，则已覆盖乳腺癌、甲状腺癌等多个癌种。 在服务端，该公司通过科技赋能实现健康险理赔自动化率超97%，并推出AI数字人"智慧小茹"提供全流程健康管理服务。 此外，泰康在线还将保险保障延伸至数字经济细分场景，面向外卖骑手等新市民群体推出的"骑手险"等产品已累计服务超440万人，为小微企业提供的"泰乐 保"系列则覆盖近30万家企业。 泰康在线方面表示，面向未来，公司已提出以"业务好、财务好、服务好、投资好"为目标的"四好"愿景。 随着保险业数字化转型步入深水区，这种将互联网基因与专业能力相结合的探索，或许能为行业高质量发展提供有益参考。 11月18日，泰康在线成立10周年。从2015年依托泰康保险集团大健康生态应运而生，到2021年迈向盈利，泰康在线的发展路径折射出整个行业数字化转型的 ...

11月18日，泰康在线正式迎来成立十周年。回首十年，中国保险业经历了从"粗放扩张"到"精耕细作"的深刻变革，近年来在金融"五篇大文章"的旗帜下，正 加速迈向高质量发展。在奔涌的时代浪潮中，泰康在线坚持创新，从行业的探索者发展为专业化互联网财险的笃行者，以"让保险更安心、更便捷、更实 惠"为初心，矢志不渝地诠释着"保险为民"的本色。 支撑这一升华的根本动力，源于泰康在线三大独特优势：依托泰康保险集团的生态支撑，形成了长远投入、深耕经营的强大定力；通过持续创新驱动，实现 了对市场需求的精准洞察，并以此倒逼产品与服务持续迭代，构筑专业壁垒；而强大的互联网基因，则让泰康在线相较于传统险企，能够更高效、更精准地 触达并服务用户。 此刻，泰康在线正深度融合其互联网特质与财险的金融属性，在发挥互联网普惠优势的同时，坚守作为持牌机构的责任与担当，以专业的风险管理能力服务 实体经济。泰康在线正与合作伙伴一道，将十年发展沉淀更精准的融入到产品服务，内化在财险专业化经营战略的具体实践当中，构建起了健康保障更全 面、出行服务更智能、数字生活更安心的"保险新生态"。 在产品端，基于对市场的深度洞察，泰康在线产品矩阵对不同人群的需求进行 ...

Core Viewpoint - The commercial health insurance industry is increasingly focusing on insurance products for patients with pre-existing conditions, particularly in the context of disease recurrence insurance, which is expected to see significant growth by 2025 [3][4]. Group 1: Market Trends and Developments - The disease recurrence insurance market has seen new product launches, such as the "Good Effect Insurance" series by Taikang Online, which expanded coverage from breast cancer to include lymphoma and lung cancer [5]. - In 2024, the health insurance premium income reached 977.4 billion yuan, marking an 8.2% growth, but the industry is facing stagnation due to market saturation among healthy individuals [6][7]. - The concept of insuring patients with pre-existing conditions is still relatively new and unclear, with estimates suggesting that the market could be around 50 billion yuan, primarily driven by supplementary medical insurance and high-end medical insurance [9]. Group 2: Product Insights - The most notable products in the disease recurrence insurance category are breast cancer recurrence insurance, which has become the largest single product in this segment, and million medical insurance that covers pre-existing conditions [12]. - The "Zhongminbao" product by Zhong An Insurance achieved rapid success, collecting 1.4 billion yuan in premiums within ten days of launch, indicating strong market demand [12][13]. Group 3: Sales and Distribution Challenges - The primary challenge in selling pre-existing condition insurance lies in distribution channels, as traditional channels are primarily focused on healthy individuals, making it difficult to reach the target demographic [16]. - Collaborations with hospitals are being explored to facilitate access to patients, but these partnerships face regulatory and operational uncertainties [17][18]. - Alternative sales strategies include leveraging pharmaceutical companies' distribution networks, which have shown some success in the market [18]. Group 4: Financial Performance and Risk Management - Currently, the existing pre-existing condition insurance products have not reported losses, but concerns remain regarding the maturity of cost control capabilities [21][22]. - The risk of high claims in million medical insurance products remains a concern, particularly for those that initially relaxed underwriting standards to attract customers [23][24]. - Insurers are employing traditional cost control methods, such as increased premiums and strict underwriting, to manage risks associated with these products [24][25].